Related references
Note: Only part of the references are listed.Blood Transfusion Management and Transfusion-Related Outcomes in Daratumumab-Treated Patients With Relapsed or Refractory Multiple Myeloma
Ajai Chari et al.
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA (2018)
F(ab′)2 Fragments to Overcome Daratumumab Interference in Transfusion Tests
Kathleen Selleng et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Daratumumab plus Bortezomib, Melphalan, and Prednisone for Untreated Myeloma
M. -V. Mateos et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Daratumumab: Therapeutic asset, biological trap!
V Deneys et al.
TRANSFUSION CLINIQUE ET BIOLOGIQUE (2018)
CD38 antibodies in multiple myeloma: back to the future
Niels W. C. J. van de Donk et al.
BLOOD (2018)
Transfusion management for patients taking an anti-CD38 monoclonal antibody
Carolina Bonet Bub et al.
HEMATOLOGY TRANSFUSION AND CELL THERAPY (2018)
Practical approaches and costs for provisioning safe transfusions during anti-CD38 therapy
Waseem Q. Anani et al.
TRANSFUSION (2017)
How do I work up pretransfusion samples containing anti-CD38?
Waseem Q. Anani et al.
TRANSFUSION (2017)
Daratumumab plus pomalidomide and dexamethasone in relapsed and/or refractory multiple myeloma
Ajai Chari et al.
BLOOD (2017)
Daratumumab (anti-CD38) induces loss of CD38 on red blood cells
Harold C. Sullivan et al.
BLOOD (2017)
Monitoring multiple myeloma patients treated with daratumumab: teasing out monoclonal antibody interference
Christopher McCudden et al.
CLINICAL CHEMISTRY AND LABORATORY MEDICINE (2016)
Monoclonal antibodies targeting CD38 in hematological malignancies and beyond
Niels W. C. J. van de Donk et al.
IMMUNOLOGICAL REVIEWS (2016)
Daratumumab monotherapy in patients with treatment-refractory multiple myeloma (SIRIUS): an open-label, randomised, phase 2 trial
Sagar Lonial et al.
LANCET (2016)
Daratumumab, Lenalidomide, and Dexamethasone for Multiple Myeloma
M. A. Dimopoulos et al.
NEW ENGLAND JOURNAL OF MEDICINE (2016)
Daratumumab, Bortezomib, and Dexamethasone for Multiple Myeloma
Antonio Palumbo et al.
NEW ENGLAND JOURNAL OF MEDICINE (2016)
International validation of a dithiothreitol (DTT)-based method to resolve the daratumumab interference with blood compatibility testing
Claudia I. Chapuy et al.
TRANSFUSION (2016)
Antibody-mediated phagocytosis contributes to the anti-tumor activity of the therapeutic antibody daratumumab in lymphoma and multiple myeloma
Marije B. Overdijk et al.
MABS (2015)
An alternative method to dithiothreitol treatment for antibody screening in patients receiving daratumumab
Amy E. Schmidt et al.
TRANSFUSION (2015)
When blood transfusion medicine becomes complicated due to interference by monoclonal antibody therapy
Marlies Oostendorp et al.
TRANSFUSION (2015)
Resolving the daratumumab interference with blood compatibility testing
Claudia I. Chapuy et al.
TRANSFUSION (2015)
Risks and adverse outcomes associated with emergency-release red blood cell transfusion
Sudhanshu B. Mulay et al.
TRANSFUSION (2013)
Daratumumab, a Novel Therapeutic Human CD38 Monoclonal Antibody, Induces Killing of Multiple Myeloma and Other Hematological Tumors
Michel de Weers et al.
JOURNAL OF IMMUNOLOGY (2011)
CD38 as a therapeutic target
George T. Stevenson
MOLECULAR MEDICINE (2006)
Share Paper
